FYB206 FDA Review: First Keytruda Biosimilar, 2027 Timeline

The headline development

Formycon AG and Zydus Lifesciences Limited have jointly announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for FYB206. FYB206 is a proposed biosimilar to Keytruda (pembrolizumab). According to the companies, this is the first publicly announced acceptance by the FDA of a filing for a proposed biosimilar to Keytruda. The acceptance moves the program from submission into active regulatory review in the US. For investors tracking biosimilars and oncology pipelines, the key takeaway is not an approval, but a formal start to the FDA review clock.

What the FDA acceptance means in practice

An FDA filing acceptance indicates the agency has completed its initial screening and will proceed with a full review of the application. The companies said the BLA was submitted in the third quarter of 2026. Under the Biosimilar User Fee Amendments (BsUFA), the FDA aims to complete its review within 12 months of submission. That 12-month target includes up to 60 days for the filing review and 10 months for the substantive review. Based on this framework, the companies indicated a decision could be expected in the third quarter of 2027. The update sets a clearer regulatory timeline, while still leaving outcomes contingent on the FDA’s full assessment.

FYB206 and the Keytruda biosimilar context

FYB206 targets pembrolizumab, the molecule marketed as Keytruda. The companies positioned the filing as a step toward expanding access to more affordable pembrolizumab therapy in the United States and Canada. While the statement highlights affordability and access, the immediate regulatory milestone is the acceptance for review, not market entry. The companies also emphasized the “first publicly announced” nature of the acceptance, which signals the competitive intensity building around high-value oncology biologics.

Development pathway: no comparative Phase III efficacy trial

A central detail in the announcement is that FYB206 was developed without a comparative Phase III efficacy trial. The companies said this approach followed a development pathway agreed upon with the FDA in early 2025. In biosimilar development, such pathway decisions can influence cost, timelines, and evidence strategy. The article does not provide clinical datasets or study results, but it does frame the program as having followed an FDA-agreed route. For market watchers, this point matters because it clarifies that the dossier was structured around an agreed regulatory plan rather than a traditional comparative Phase III efficacy design.

Canada filing: Health Canada submission also made

Alongside the US BLA progress, the regulatory dossier for FYB206 has also been submitted to Health Canada. The announcement does not specify timing details for the Canadian review. However, the dual filing underscores that the program is being advanced for North America, consistent with the commercial territory defined in the partners’ agreement. The companies did not announce any approval or review acceptance status for Canada in the provided text, only that the dossier was submitted.

The Formycon-Zydus deal structure and responsibilities

Formycon and Zydus entered into an exclusive licensing and supply agreement for FYB206 in the United States and Canada in December 2025. Under the arrangement described, Formycon is responsible for completing development, preparing and filing regulatory dossiers, and supplying the product. Zydus holds exclusive commercialization rights for the US and Canada and is expected to commercialize FYB206 in both markets, subject to regulatory approval. The companies also noted that commercialization is subject to the resolution of any intellectual property issues. The update therefore ties regulatory progress directly to a pre-defined partnering framework rather than a new transaction.

Milestone payment triggered by the FDA acceptance

The acceptance of the BLA for review triggers a regulatory milestone under the licensing agreement. As a result, Formycon becomes entitled to a milestone payment from Zydus. The announcement does not disclose the milestone amount or payment timing. Still, the detail is important because it links a regulatory event to a contractual financial consequence. For investors, such milestones can affect near-term cash flows even before product approval, although the actual quantum is not provided here.

Market impact: what changes and what does not

The immediate change is status: FYB206 has transitioned from submission to active FDA review. The companies also provided a review timeline reference under BsUFA, pointing to a potential decision in Q3 2027 based on the Q3 2026 submission. What does not change is regulatory risk: FYB206 remains investigational and has not received regulatory approval in any country. The partners also highlighted that commercialization will depend on regulatory approval and intellectual property considerations, which remain open items in the disclosed text. Investors and industry participants therefore have a clearer calendar anchor, but not a reduced set of uncertainties.

Key facts at a glance

Timeline snapshot

Why this matters for the biosimilars landscape

Keytruda is a widely used oncology biologic, and the partners are explicitly positioning FYB206 as a step toward broader access in North America. The announcement also highlights the growing relevance of regulatory strategies where development plans are aligned with the FDA early, including approaches that do not rely on a comparative Phase III efficacy trial. At the same time, the companies are careful to state that FYB206 is investigational and not approved anywhere, which sets limits on how investors should interpret the milestone. The most concrete near-term implications from the text are the formal start of FDA review and the milestone payment entitlement for Formycon under its agreement with Zydus.

Conclusion

The FDA’s acceptance of FYB206’s BLA for review gives Formycon and Zydus a defined regulatory pathway for a proposed Keytruda biosimilar in the US, with a decision window indicated for Q3 2027 based on the stated BsUFA timeline. The partners have also submitted a dossier to Health Canada and reaffirmed their division of responsibilities in the US and Canada under the December 2025 agreement. Next, the market’s focus will remain on the FDA’s substantive review process and any subsequent regulatory steps that the companies publicly disclose.